XTX Topco Ltd purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 23,107 shares of the biotechnology company's stock, valued at approximately $396,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after buying an additional 80,302 shares during the last quarter. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after acquiring an additional 50,399 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in ADMA Biologics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock worth $64,654,000 after acquiring an additional 102,692 shares during the last quarter. Perpetual Ltd bought a new stake in shares of ADMA Biologics in the 4th quarter worth $62,300,000. Finally, Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics during the third quarter valued at about $61,858,000. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Trading Up 8.9 %
NASDAQ ADMA opened at $21.39 on Wednesday. The business's fifty day moving average is $18.44 and its 200-day moving average is $18.23. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market capitalization of $5.06 billion, a price-to-earnings ratio of 76.39 and a beta of 0.53. ADMA Biologics, Inc. has a one year low of $6.23 and a one year high of $23.64.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.
View Our Latest Analysis on ADMA
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
